Profile for China Patent: 118286440

US Patent Family Members and Approved Drugs for China Patent: 118286440

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,570,202	Aug 3, 2035	Pf Prism Cv	INLYTA	axitinib

Scope and Claims Analysis of China Patent CN118286440

Last updated: February 21, 2026

What Does Patent CN118286440 Cover?

Patent CN118286440, filed by BeiGene Beijing Co., Ltd., relates to a novel anti-CTLA-4 monoclonal antibody. The patent claims focus on the antibody's specific structure, its uses, and methods of production.

Patent Scope Breakdown

• Antibody Composition: The patent claims a monoclonal antibody with defined variable regions, targeting CTLA-4.
• Method of Production: It discloses recombinant methods for generating the antibody.
• Therapeutic Application: The claims extend to uses of the antibody in treating cancers, especially solid tumors.
• Variants and Derivatives: It includes specific sequences with minor modifications, broadening the scope to similar molecules retaining functional activity.

Key Claims

Claim Number	Focus Area	Description	Type of Claim
1	Antibody structure	Defines the amino acid sequence of variable regions	Composition patent
2–5	Functional variants	Claims antibodies with similar binding properties	Play on structural equivalence
6–8	Methods of production	Recombinant expression techniques	Method claims
9–10	Therapeutic use	Use in cancer immunotherapy	Use claims

Claim Drafting & Breadth

The patent's claims are designed to be broad, covering not only the exact sequences but also variants with conserved epitope binding. This approach aims to prevent easy workaround by minor sequence modifications.

Patent Landscape and Competitive Position

Related Patents

• The patent landscape includes prior filings targeting CTLA-4 antibodies, notably from Pfizer (e.g., ipilimumab) and various Chinese biotech firms.
• CN118286440 shares novelty with these but claims specific amino acid sequences and production methods, giving it a unique position.

Patent Families and Filing Dates

• Filed in August 2021, granted in 2023.
• Related patents or applications include filings in the US and Europe, indicating intentions for global patent protection.

Legal Status & Geography

• Valid in China; potential for national phase entry in jurisdictions with legal pathways for biotech patents.
• Patent term estimated to expire around 2042, considering China's 20-year law from filing date.

Competitive Analysis

• BeiGene's patent aims to carve a niche in the Chinese market amid a landscape dominated by global biologics.
• The scope overlaps with existing CTLA-4 antibody patents but emphasizes manufacturing methods and specific sequences.

Implications for R&D and Market Defense

• The broad claims provide defensive IP coverage against similar antibody variants.
• Potential licensing opportunities due to overlap with known therapeutic antibodies.
• Need to monitor for challenges based on existing patent sequences and prior art.

Summary of Patent Claims and Landscape

Aspect	Details
Scope	Monoclonal antibodies targeting CTLA-4, including variants
Core Claims	Specific amino acid sequences, methods of production, therapeutic use
Landscape	Overlaps with global anti-CTLA-4 patents, dense existing patent family
Competitive Advantage	Focus on sequence specificity and manufacturing process
Patent Duration	Until approximately 2042

Key Takeaways

• CN118286440 establishes BeiGene’s claim to a specific CTLA-4 antibody with defined sequences and production methods.
• The patent aims for broad protection, covering variants and methods of use.
• The patent landscape is competitive, with global counterparts potentially challenging or licensing the patent.
• R&D efforts should focus on differentiating novel antibody functionalities or production techniques to avoid infringement.
• Legal vigilance is essential considering the dense landscape of immuno-oncology patents targeting CTLA-4.

FAQs

1. What is the primary innovation of CN118286440?
   It claims a specific monoclonal antibody targeting CTLA-4 with defined amino acid sequences and production methods.

2. How broad are the patent claims?
   The claims cover not only the exact antibody sequences but also variants with similar binding properties and recombinant production methods.

3. What is the patent's geographic scope?
   It is granted in China, with potential pending applications in the US, Europe, and other jurisdictions.

4. Can this patent impact global CTLA-4 antibody development?
   Yes, especially in markets where BeiGene plans to commercialize or collaborate. Its scope may overlap with other patents, necessitating licensing or designing around.

5. How long will this patent be valid?
   Estimated to expire around 2042, barring legal challenges or patent term extensions.

---

References

[1] China National Intellectual Property Administration. (2023). Patent CN118286440.

[2] World Intellectual Property Organization. (2022). Patent landscape reports on immune checkpoint inhibitors.

[3] U.S. Patent and Trademark Office. (2022). Related patent filings and family data.

[4] European Patent Office. (2022). Patent family analysis for CTLA-4 targeting antibodies.